Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs

In recent years, therapeutic drug monitoring (TDM) of intravenous administration of 5-fluorouracil (5-FU) has resulted in reduced toxicity and improved efficacy. Prodrugs of 5-FU were developed to reduce toxicity, extend the duration of action, and increase tumour selectivity of 5-FU. These drugs ar...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 40; no. 8; pp. 4655 - 4661
Main Authors Hashimoto, Yasuhiro, Yoshida, Yoichiro, Yamada, Teppei, Aisu, Naoya, Yoshimatsu, Gumpei, Yoshimura, Fumihiro, Hasegawa, Suguru
Format Journal Article
LanguageEnglish
Published Athens International Institute of Anticancer Research 01.08.2020
Subjects
5-Fluorouracil
Chemical compounds
Drugs
Intravenous administration
Monitoring
Prodrugs
Selectivity
Toxicity
Tumors
Online AccessGet full text

Cover

More Information
Summary:In recent years, therapeutic drug monitoring (TDM) of intravenous administration of 5-fluorouracil (5-FU) has resulted in reduced toxicity and improved efficacy. Prodrugs of 5-FU were developed to reduce toxicity, extend the duration of action, and increase tumour selectivity of 5-FU. These drugs are important in daily practice because of their ease of administration. Dose adjustment of 5-FU prodrugs by TDM is expected to reduce its toxicity and improve its efficacy. This review focuses on data from a recent study of personalized treatment using TDM of 5-FU and its prodrugs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14464